personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Age macular degeneration-alzheimer disease: interest of ophthalmologic exam in detection, follow-up of AMD, of Alzheimer disease, its relevance to highlight the links and correlations between AMD and AD

Session Details

Session Title: Quick Fire Free Paper Session 01

Session Date/Time: Thursday 26/09/2013 | 08:30-10:30

Paper Time: 08:40

Venue: Hall G1 (Level 2)

First Author: C.Gonzalez FRANCE

Co Author(s):                  

Abstract Details

Purpose:

To evaluate the importance of ophthalmologic exam in AMD and AD, the impact of AMD on Alzheimer disease and vice versa, and their in-between correlation and relationship.

Setting:

Interventional, non comparative, retrospective case series

Methods:

PATIENTS: AMD patients: 180 patients, 3 Groups A, B, C. A: 52 AMD patients with first stage AMD (drusen, drusenoid PED, pigment, small atrophic areas), B: 48 Atrophy AMD patients with predominant atrophic areas, C:80 Neovascular AMD patients, with Neovascular AMD. AD patients: 180 patients, 4 groups .I: 53 Normal or no significative patients; II: 95 MCI patients,( 4 subgroups: mild, moderate, intense , severe); III : 22 Early AD; IV:10 AD. EXAM: ophthalmologic exam included ETDRS visual acuity (VA), complete ophthalmic examination, Fundus examination, autofluorescence imaging (FAF), (Region Finder Software, particularly for atrophic areas), optical coherence tomography (Spectral Domain OCT) (OCT en face software), and fluorescein angiography (FA) and ICG when Neovascular complication (Spectralis HRA-OCT). Cognitive evaluation is done with MMSE: Mini Mental State Examination (Folstein, GRECO), score allow to determine various groups and subgroups. Each AMD patient, more than ophthalmologic exam would have cognitive evaluation. Each AD patients, more than cognitive exam, would have ophthalmologic evaluation.

Results:

AMD patients;73% patients in group A, 77,5% in group B, 63% in group C have mild cognitive impairment (MCI).In MCI subgroups, results are progressively decreasing and similar in group A and B, lower and homogeneous in group B. Cognitive impairment differ between AMD subgroups. It’s moderate in group A (normal score:37%), higher in group B and C, and more in group B( normal score:22,5%) than in group C (normal score:34%) , but early AD is only present in group C (3%).AD patients;43% patients with cognitive impairment present AMD. AMD ophthalmologic signs are predictive and precursor for AD. Fundus examination and even more (FAF, OCT) are useful and needed to enhance AD screening and follow-up as to detect AMD in AD patients.

Conclusions:

The AMD-AD correlation allows us to improve detection, follow-up, screening of both AMD and AD pathologies and furthermore progress in etiopathogenic knowledge and therapeutic prospects.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy